ResearchGate

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/354829992

Efficacy of three lytic bacteriophages for eradicating biofilms of multidrug-resistant Proteus mirabilis

Article *in* Archives of Virology · December 2021

DOI: 10.1007/s00705-021-05241-5

CITATIONS
8

READS
235

5 authors, including:

Ahmed Esmael
University of Nebraska at Lincoln
49 PUBLICATIONS **456** CITATIONS
SEE PROFILE

Sabah abo-elmaaty
Benha University
30 PUBLICATIONS **129** CITATIONS
SEE PROFILE

Mervet Gameel Hassan
Benha University
75 PUBLICATIONS **335** CITATIONS
SEE PROFILE

All content following this page was uploaded by Sabah abo-elmaaty on 30 January 2023.

The user has requested enhancement of the downloaded file.

''Studies one the application of bacteriophages and silver_nanparticles in the treatment of *pseudomonas spp.* Isolated from Benha University hospital''

Abstract

This study aimed to studies on the applications of bacteriophages, as a biocontrol agent, against certain antibiotic-resistant bacteria causing Chronic wound. Here, Chronic wound caused by *pseudomonas aeruginosa* were isolated and characterized biochemically using the automated VITEK® 2 system. Antibiotic sensitivity pattern of the isolated Chronic wound bacteria was assessed against selection of antibiotics. these bacteria exhibited resistance against most of the tested antibiotics.To overcome this problem, using phage VB_PseM-EB-E44 were isolated, identified, and applied to control the growth of *pseudomonas aeruginosa*, respectively. Phage was identified morphologically using TEM and exhibited that VB_PseM-EB-E44 is related to Myoviridae, This phage showed high lytic activity, high stability, and a narrow host range. The *P. aeruginosa* phage VB_PseM-EB-E44 was thermostable at temperatures ranging from 10 to 60 °C, however, and the titer decrease significantly at 70°C, no viable phages were detected at 80°C for 60 min. Phage VB_PseM-EB-E44 stabled at pH range 3 to 9 for 1h, lost its activity at pH 2, 10, 11, 12. Since. The one-step growth curve of phage showed burst size of (60) PFU/cell with latent period of (15) minute for *P. aeruginosa* phage. *Pseudomonas aeruginosa* is one of the most common causes of health care-associated infections, this review collects data of all the *P. aeruginosa* phage sequenced to date, this review further addresses *in vitro* and *in vivo* results obtained by using silver_nanparticles and phages to treat or prevent *P. aeruginosa* infections in addition to the major hurdles related with this therapy. This study indicates that the isolated bacteriophages are promising biocontrol agents that could challenge antibiotic-resistant Chronic wound bacteria to announce new successful alternatives to antibiotic.

Introduction

Pseudomonas aeruginosa is a gram-negative, aerobic, non-spore forming rod that is able of causing a assortment of infections in both immunocompromised and immunocompetent hosts (Kerr and Snelling, 2009). *Pseudomonas aeruginosa* scarcely existed as part of the human microflora in healthy individuals is nonglucose fermenter rod, *P. aeruginosa* is an opportunistic pathogen for humans lead to a broad spectrum of disease such as burn, urinary, septicemia and respiratory infections (Yang *et al., 2011). P. aeruginosa* is an aerobic Gram-negative commonly existed in different environments such as soil, plant, and water (Wagner *et al.*, 2008; Pereira *et al.*, 2014). That is capable to infect various organisms, including animals, humans, and plants (Lister *et al.*, 2009; Breidenstein *et al.*, 2011; Pereira *et al.*, 2014). *P. aeruginosa* may not be a exemplary pseudomonad in natural environments. *P. aeruginosa* requirements a simple nutrition supply, and has ability even grow in distilled water, it has ability also grow well in a medium containing ammonium sulphate (nitrogen source) and acetate (carbon source), the optimum temperature for growth is 37^0C, but *P. aeruginosa* also grows at high temperatures 42^0C helps distinguish it from many other Pseudomonas species (Nazina *et al.*, 2005). But this widespread bacterium will grow in the presence of NO3 but in the absence of O2 (Robertson *et al.*, 1989).

Most strains of *P. aeruginosa* produce one or more pigments, containing pyoverdine (fluorescent yellow-green) and pyocanin (blue-green), and pyorubin (red-brown) (Young *et al.,* 1947; Meyer *et al.,* 2000*).* Former investigations have suggested that pyocyanin not only contributes to the persistence of *P. aeruginosa* in the lungs of CF patients, but also interferes with many mammalian cell functions, containing ciliary beating, cell respiration, epidermal cell growth, calcium homeostasis and prostacyclin release from lung endothelial cells (Caldwell *et al.*, 2009). *P. aeruginosa* caused nosocomial infections ivolved pneumonia, surgical site infections, bloodstream infections, and urinary tract infections, skin infections in the case of burn injuries. Repeated infections and Chronic sinopulmonary colonisation from *P. aeruginosa* are seen in patients with cystic fibrosis (CF), infections caused by *P. aeruginosa* are not only widespread (Rello *et al.*, 2002; Rello *et al.*, 2005). Most of the injuries caused by *P. aeruginosa* are noticeably complex to treat using conventional antibiotic therapies, *P. aeruginosa* possess an arsenal of virulence factors enabling it to circumvent host defenses and invade host cells (Wagner *et al.*, 2008; Ballok *et al.*, 2013).These mechanisms of virulence

contains dissembled factors such as elastase, pyocyanin, proteases, exoenzyme S, exotoxin A, and exoenzyme S and also cell-associated factors such as pili, lipopolysaccharide (LPS), and flagella (Wagner *et al.*, 2008; Strateva *et al.*, 2011). All of these resistance mechanisms and virulence factors takes part in increased *P. aeruginosa* pathogenicity, resulting in infections that are consequently very complicated to treat (Driscoll *et al.*, 2007; Fajardo and Martínez 2008; Breidenstein *et al.*, 2011).

Most of the infections caused by *P. aeruginosa* are noticeably hard to treat using ordinary antibiotic therapies, since this microorganism exhibit high actual resistance to a large range of antibiotics, containing, fluoroquinolones, β-lactams and aminoglycosides (Breidenstein *et al.*, 2011). *P. aeruginosa* is extremely isolated from hospital medical equipment, because of the bacterium's capability to survive in biofilms (Inglis,1993; Donlan, 2001). Infections with multidrug-resistant *P. aeruginosa* require new therapies with present care focused on silver_nanparticles and bacteriophages (phages). Silver compounds have been historically used to control microbial proliferation (Wadhera and Fung, 2005). The antifungal and antibacterial effect of Silver Nanoparticles AgNPs, even against antibiotic-resistant bacteria (Wright *et al.*, 1994; Wright *et al.*, 1999), has been demonstrated in *in-vitro* conditions. Nowadays, silver compounds are routinely applied in a wide array of industrial and sanitary fields, such as coating of catheters and surgery material, the production of synthetic compounds for odontology, treatment of burn injuries, homeopathic medicine, water purification and textile fabrics (Spencer, 1999; Klasen, 2000; Wadhera and Fung, 2005; Atiyeh *et al.*, 2007; 58Hwang *et al.*, 2007), and posses low toxicity to human cells, high thermal stability and low volatility (Durán *et al.*, 2007).

Biodegradable nanoparticulate systems have received considerable attention as potential drug delivery vehicles. Chitosan (CS), a polysaccharide known to be a favorable pharmaceutical material because of its biocompatibility and biodegradability, forms an ideal hydrophilic carrier system (Kreuter, 1991). Moreover, chitosan has been shown to be non-toxic and tissue compatible in a range of tests. Nanoparticles, which can be produced with a wide variety of polymers and nanotechnologies, have also been recently proposed as delivery systems for peptides and proteins through the pulmonary route (Alonso, 2020). In this respect, chitosan is avery attractive polysaccharide due to its reported low toxicity, biodegradability and mucoadhesivity (Cohen and Bernstein, 2020). Bacteriophages are bacterial viruses which were

discovered about a century ago (Twort, 1961; Felix, 1917). Phages are viruses that infest bacteria; they cause lysis of bacterial cells (lytic phages) and disconnect the metabolism of bacteria. Specially, any species of phage attacks only certain bacteria as its host; it frequently does not effect total microbial biomass (Wang *et al.*, 2000). According to their life cycles, phages may be divided into two classes: temperate phages (lysogenic) and virulent phages (strictly lytic). Temperate phages commonly combine their genome into the host chromosome or sometimes save it as a plasmid that is transmitted, by cell division, to the daughter cells (Guttman *et al.*, 2004; Little, 2005).

Lytic phages adsorb to the host cell surface, inject and replicate their DNA, and then stimulate host cell lysis, resulting in the liberation of progeny phages that may starting another cycle of infection (Guttman *et al.*, 2004). In addition to the lysogenic and lytic types of bacteriophage infection, other types may exist. The filamentous bacteriophages typically cause a persistent infection of bacterial cells which does not kill the host but results in continued excretion of viral particles (Harper *et al.*, 2014). During effective infection, a strictly virulent phage produces typically more than 100 copies of itself (Szafranski *et al.*, 2017). If the bacterial cells are larger than number of phages, next many generations the population of phages will exceed that of bacterial cells, finally the total bacterial cells will lyse (Wang *et al.*, 2000). Next the arrival of the golden era of antibiotics, together with the scientific difference concerning the utilize of phages because of poorly controlled trials, the benefit of phage therapy decreased quicly (Sulakvelidze *et al.*, 2001). Antibiotics were inexpensive and frequently effective against bacterial diseases and thus were considered the better solution to fight bacterial diseases. So, following World War II, phage therapy was ignored in the Western world but kept being utilized in Poland and the Soviet Union (Sulakvelidze *et al.*, 2001; Chanishvili, 2012). One alternative that has recently revived benefit is phage therapy, top proposed in the early 20th century by Felix d'Herelle. Besides, several clinical studies have clear that the utilize of phages in both animals and humans active and without side effects (Burrowes *et al.*, 2011; Patey *et al.*, 2019). Lytic phages are considered as possible alternative candidates to traditional antibiotics for a large range of oral bacterial infections (Lee *et al.*, 2019). Phages of the *Pseudomonas* genus were first described in the middle of the 20th century (Kellenberger and Kellenberger, 1957; Holloway *et al.*, 1960).

Since *Pseudomonas aeruginosa* is one of the most problematic opportunistic pathogens involved in hospital-acquired infections (Aloush *et al.*, 2006; Driscoll *et al.*, 2007). The possibility to handel efficiently multidrug resistant (MDR) bacteria with phages has recently spurred regenerate interest in this field (Gordillo Altamirano and Barr, 2019). Phages exhibit several features over traditional antibiotics, the leading one being their specificity, since they usually target a single bacterial species, while dismissal the host microbiota unaffected. Secondly, phage replication is dependent on the existence of the host-bacterium and is therefore self-limiting. The main interest for therapeutic utilize of phages are the potential to transfer virulence or antibiotic resistance genes, requiring in depth analysis of the phages genomes (Torres-Barcelo, 2018). More than 90% of phages have large, double stranded DNA genomes located in heads with icosahedral symmetry, with tails of diversity lengths. All fall within the order Caudovirales and belong to three major morphological groups. These are the families Podoviridae (with short, noncontractile tails), Myoviridae (with long, rigid, contractile tails), and the Siphoviridae (with long, flexible, noncontractile tails). The genome and morphology type of the remaining phage families are highly changeable, and they can owns RNA or DNA genomes. One notable group with single-stranded DNA genomes (Inoviridae) appears as long filaments (Maniloff, 2006). For therapeutic utilizes, obligately lytic phages are so desired. Due they result in fast killing of their target host cell, bacteriophage numbers rise rapidly and transduction is relatively unusal. DNA sequencing of bacteriophage genomes is now utilized to confirm both absence of unfavourable elements and identity, like functional bacterial toxins or lysogenic components. Like toxin genes are known to be particularly related with some bacteriophages, for example the Shiga toxins of Escherichia coli, which would be of real interest if existent in a therapeutic bacteriophage formulation. Early tryings to utilize phages for therapy of bacterial infections were compromised by rareness of understanding of the nature of the agents involved. Work in this area dates back to 1919, but as delayed as 1941, reliable reports were yet challenging the theory that bacteriophages were viral in nature (Krueger and Scribner, 1941). In this study, bacteriophage isolation and identification were achieved as novel candidates appropriate for bacteriophage therapy silver_nanparticles against *P. aeruginosa* as alternatives to conventional antibiotics.

MATERIALS AND METHODS

Bacterial strains and growth conditions

This study was performed on antibiotic-resistant chronic wound isolates that were isolated formerly from patients with wound plaques in Qalubiya governorate, Egypt. All strains were stored at -80°C in Brain-Heart-Infusion broth complemented with 20% (v/v) glycerol. Freshly overnight grown cultures were prepared by inoculating a single colony into 10 ml of Basal salt medium with yeast extract and incubating for 16 h at 37°C with shaking at 200 rpm.

Morphological and Biochemical identification of the chronic wound bacteria

Biochemical and Morphological identification (Table S1, Supplementary data) of the chronic wound bacteria were done according to Bergey's Manual of Systematic Bacteriology. These isolates were approved by VITEK® 2 COMPACT automated instrument for ID/ AST testing (Pincus, 2006)

Antibiotic sensitivity test

Antibiotics sensitivity testing was performed on Mueller-Hinton agar by the disc diffusion method (Biemer, 1973) for the following antibiotics (Oxoid, UK); Aztreonam (ATM, 30 µg), Amoxicillin (AX, 25 µg), Tobramycin (TOB, 10), Streptomycin (S, 10), Imipenem (IPM , 10), Ceftazidime (CAZ, 30 µg), Cefotaxime (CTX, 30 µg), Cefaclor (CEC, 30), Cephalexin(CL, 30), Ceftriaxone(CRO, 30), Cefoxitin (FOX, 30), Ciprofloxacin (CIP, 5 µg), Norfloxacin (NOR, 10 µg), Ofloxacin(OFX, 5) and Trimethoprim/sulfamethoxazoe (SXT, 25). The results were interpreted conferring to the guidelines of the Laboratory and Clinical Standards Institute (CLSI) (Wayne, 2010)

Preparation of Silver and Chitosan nanoparticles

Silver nanoparticles have been prepared by chemical reduction method as reported by Turkevich (Turkevich *et al.*, 1951; Lee and Meisel, 1982). A solution of $AgNO_3$ has been used as Ag^{1+} ions precursor. The PVP has been used as stabilizing agent and borohydrate as mild reducing agent. The color of the solution slowly turned into grayish yellow, indicating the reduction of the Ag^{1+} ions to Ag nanoparticles.

Chitosan nanoparticles were prepared according to the ionotropic gelation process (Hasanin *et al.*, 2018). Blank nanoparticles were obtained upon the addition of a tripolyphosphate (TPP) aqueous solution to a Chitosan solution

Susceptibility tests assess the antimicrobial activity of nanoparticles

Nano silver and Nano chitosan were brought from specialized company in distilled water to different concenteration (1, 0.5, 0.25, and 0.125). The test were performed by the disc diffusion method on muller hinton agar media .In this experiment we used sterilized paper disc (0.5) impregnated with different concentration of nanoparticles. Bacteria overnight cultured was spread-platedon muller hinton agar plate then sterilized disc were put over them and the plates were incubated at 37^{0c} for 24h ,after this time the inhibition zone were measured to determine their antimicrobial activity (George *et al.*, 2010)

Isolation of Bacteriophages

The *clinical* isolates *P. aeruginosa* was utilized as hosts for the propagation, and isolation of bacteriophages. Samples from 15 healthy individuals and 85 burn injuries in affected patients and drainage samples from dermatology clinics have been collected from Benha city, Qalubiya governorate, Egypt for bacteriophage screening. The collected samples were centrifuged at 10,000 rpm for 10 min, supernatant fluids were collected, and membrane filtered using 0.22 µm membrane filters. Enrichment of phages and isolation were performed as described formarly (Van Twest and Kropinski, 2009). Briefly, 5 ml of a 0.22 µm-filtered sample was mixed with 20 ml double-strength Tryptic Soybean Broth (TSB) medium and 100 µl of a mid-log culture of *P. aeruginosa* strain vB-pesM-EB-E44 and incubated for 48 h at 37°C with shaking at 200 rpm. Later, bacteria were harvested by centrifugation at 10,000 rpm for 10 min, supernatant fluids have been recovered, and membrane-filtered using 0.22- µm Millipore filters (Millipore, Ireland). Phages were screened by spotting five microliters of the enriched samples onto double-layered plates containing a lawn of the indicator bacteria strain and incubated for 48 h at 37°C (Huang *et al.*, 2018). Plates were inspected for the presence of clear lysis zones, the clear zone was cut

and propagated in a fresh culture. This lysate was serially diluted, spotted onto double-layered plates, and incubated as described above.

Transmision electron microscopy of bacteriophage

Ten microliters of highly purified phage suspension were fixed onto 300- by 300-mesh copper grids (Electron Microscopy Sciences) supported by carbon-coated Formvar film (Ackermann, 2012). After 5 minutes, fixed phages were negatively stained with 2% (w/v) aqueous uranly acetate, pH 7.2 for 1 min, andair-dried at room temperature for 1 h. Transmission electron microscope (A JEOL JEM-2100) was used for attaining the phage particle images at the Electron Microscope Facility, Al-Azhar University, Egypt.

One-step growth curve

Phages growth phases and burst size were determined as described formarly (Huang *et al.*, 2018). A known number of an exponential-phase culture (ca. 4×10^7 CFU/ml) of each bacterial host was infected with each specific phage individually at an MOI of 1, phages were allowed to adsorb for 5 min at room temperature. The mixture was then centrifuged at 5,000 rpm for 5 min and the supernatant was decanted to remove free-unbound phages. The bacteria-phage pellet was then washed twice and resuspended in 10 ml of TSB and maintained at 37°C with continuous shaking. At appropriate times phage titers were enumerated using plaque assay (Kropinski *et al.*, 2009).

Determination of the bacteriophages host range

The host range for the isolated phage vB-PesM-EB-E44 was determined against a collection of twenty bacterial isolates as formarly described with some modifications (Clokie and Kropinski, 2009; Danis-Wlodarczyk *et al.*, 2015).Ten microliters of each phage suspension (about 108 PFU/ml) were spotted, in duplicate, onto the TSA bacterial lawn plates and incubated at 37 °C for 16–18 h.

Thermal and pH stability

Thermal and pH-stability of the isolated phages were tested as described before (Huang *et al*., 2018) For the assessment of thermal stability, 900 µl of preheated 0.22 µ m filter-sterilized SM buffer (5.8 g NaCl, 2.0 g MgSO4 •7H2 O, 50 ml 1 M Tris-HCl pH 7.4, in 1-liter dH2 O) were added to 100 µl of each of phage lysates (8 log10 PFU/ml). Tubes were incubated at 10°C, 37°C, 50°C, 60°C, 70°C, and 80°C for 1 h. Aliquots were collected After 60 min of incubation to determine phage titers. For pH-stability assessment, phage lysates (8 log10 PFU/ml) were added to tubes containing sterile SM buffer with pH values ranging from 2-12 adjusted with NaOH and HCl. The tubes were incubated at 37°C for 60 min. Subsequently, the phage solutions were serially diluted and the recovered phage titers were determined using bacterial hosts employing the double-layer agar method (Kropinski *et al*, 2009). Each temperature and pH treatment was performed in triplicates and the average of triplicate counts was calculated. Phage thermal/pH stability (%) = (Recovered phage titers following the treatment / Initial Phage titer before treatment) ×100%

RESULTS

Bacteria and antibiotic sensitivity testing

In the current study, *P. aeruginosa* were isolated formerly from infected patients with chronic wound. The isolates were identified biochemically using conventional methods (Table S1, Supplementary data) and were confirmed by Vitek 2 system. An antibiotic sensitivity test was performed for isolated bacteria against a selection offifteen antibiotics (Fig. S1, Supplementary data). Qualitative data from the antibiograms (Table 1) revealed that *P. aeruginosa-S-EB3* were resistant to at least twelve antibiotics with a resistance percentage of 87% against the tested antibiotics, respectively. *P. aeruginosa-S-EB3* resisted Tobramycin, Amox0icillin, Norfloxacin, Cefaclor, Cephalexin, Ceftriaxone, Cefoxitin, Streptomycin, Vancomycin, Ceftazidime, Ofloxacin, and Trimethoprim/sulfamethoxazoe but was susceptible to Aztreonam.

Table1. Antibiotic sensitivity pattern of the isolated chronic wound bacteria against a selection of fifteen antibiotics

Antibiotic Category	**Antibiotic used**	***P. aeruginosa-S-EB3***
monobatams	Aztreonam (ATM, 30 µg)	S
Pencillins aminogycosiides	Amoxicillin (AX, 25 µg) Tobramycin(TOB, 10) Streptomycin(S, 10)	R R R
carbapenems	Imipenem(IPM , 10)	I
Cebhalosbporins	Ceftazidime (CAZ, 30 µg) Cefotaxime (CTX, 30 µg) Cefaclor(CEC, 30) Cephalexin(CL, 30) Ceftriaxone(CRO, 30) Cefoxitin(FOX, 30)	R R R R R R
fluoroquinolones	Ciprofloxacin (CIP, 5 µg) Norfloxacin (NOR, 10 µg Ofloxacin(OFX, 5)	I R R
sulfonamides	Trimethoprim/sulfamethoxazoe (SXT,25)	R

Susceptibility tests of Silver and Chitosan Nanoparticles



Figure 1. (A):Nano Sliver susceptibility test showing zones of clearance surrounding paper Discs (a=1mg/ml, b=0.5mg/ml, c=0.25mg/ml, d= 0.125mg/ml) aganist multidrug resistance *P. aeruginosa-S-EB3*, (B): Nano chistosan susceptibility test isn't effective on the bacteria with different concentration in (e=1mg/ml, f=0.5mg/ml, g=0.25mg/ml, h= 0.125mg/ml) aganist multidrug resistance *P. aeruginosa-S-EB3.*

Morphology of bacteriophage

phage plaque morphology (Fig. A) targeted chronic wound causing bacteria, *P. aeruginosa* was successfully obtained after a screening of 100 samples of injury. Successive double soft-layer agar assays led to pure phage isolation, titrated and processed at 4°C. (Fig. A) shows clear plaques produced by VB_PseM-EB-E44 on *P. aeruginosa* -S-EB3 as host strains respectively. Phage VB_PseM-EB-E44 produces small circular clear plaques with a diameter of 2 mm.The concentrations of phage was $4x10^7$ PFU/ml. Transmission Electron microscopy (Fig. B) allowed us to infer that VB_PseM-EB-E44 belong taxonomically to order Caudovirales. Dimensions of the isolated phage was measured and summarized in Table 2. The particle of VB_PseM-EB-E44 had a contractile tail with 192.3 nm in length and head with a diameter of about 61.5 nm a typical member of Myoviridae family.

B

Fig.2.(A): Plaques phenotypes and TEM morphology of the isolated phage. (A) Images of bacterial plaques formed by the isolated phage in top-agar lawns of *P. aeruginosa-S-EB3*, plaque appearance was detected and imaged after culturing 48 h on their hosts. (B) TEM micrographs of phages VB_PseM-EB-E44 was negatively stained with 0.2% uranyl acetate as described in Materials and Methods. Scale bar= 100 nm.

Table2. Dimensions of the isolated phage

Phage	Bacterial host	Plaques diameter (mm)	Head diameter (nm)	Tail length (nm)	Proposed family
VB_PseM-EB-E44	*P. aeruginosa*-S-EB3	2	61.5± 2	192.3± 1	*Myoviridae*

Growth-kinetics and host range

One-step growth kinetics of the isolated phage (Fig. 3) exhibited typical growth kinetics of most bacteriophage. Phage VB_PseM-EB-E44 gave burst size of 60 PFU/cell respectively with latent periods of 15 minutes. The host range of the isolated phages was estimated, and results were summarized in Table 3. phage established a narrow spectrum of lytic activity.



Fig.3. One-step growth curves of phage VB_PseM-EB-E44 on their corresponding hosts. Data shown are the mean of two replicates and error bars show the deviation in the values.

Table 3. Host ranges of the isolated phage

Species	Strain ID number	Lysis by bacteriophage Phage VB_ PseM-EB-E44
Pseudomonas aeruginosa	*P.aeruginosa-S-EB1*	-
	P.aeruginosa-S-EB2	-
	P.aeruginosa-S-EB3	+
	P.aeruginosa-S-EB4	-
	P.aeruginosa-S-EB5	-
	P.aeruginosa-S-EB6	-
	P.aeruginosa-S-EB7	-
	P.aeruginosa-S-EB8	-
	P.aeruginosa-S-EB9	-
Klebsiella Pneumoniae	Kp01	-
S. aureus	Sa01	-
	SA101	-
	SA1E	-
	EG-AE1	-
E. coli	Ec01	-
Acinetobacter baumannii	Ab01	-
	Ab02	-
Salmonella enteritidis	EG.SmE1	-
	EG.SmE2	
Proteus	Pm1	-
Number (N=20)		2

"–," no clearing; "+," completely clear.

Thermal and pH stability

Thermal and pH stability patterns of phage VB_PseM-EB-E44 was tested based on residual phage titers after incubation under different pH values and temperatures (Fig. 4). The *P. aeruginosa* phage (VB_PseM-EB-E44) was thermostable at temperatures ranging from 10 to 60 °C. But, after heating at 70°C for 60 min, phage titers decreased by 60% and no viable phages were detected after heating at 80°C for 60 min. Phage VB_PseM-EB-E44 resisted a pH range between pH 4 and 9 for 1h. lost its activity at pH 2, 10, 11, 12. (Fig. 4).



Fig.4. Thermal and pH tolerance test of phage VB_PseM-EB-E44. (A)Thermal tolerance, and (B) pH stability of VB_PseM-EB-E44 phage, respectively. Temperature experiments were performed for 1 h at pH 7. pH tolerance was performed for 60 min at 37°C. Data showed the percentages of the remaining phages after each treatment as normalized from the control. Data shown are the mean of two replicates and error bars show the deviation in the values.

DISSCUSION

P. aeruginosa is related to a potent increase in human infections (Kerr and Snelling, 2009). This opportunistic human pathogen founds chronic or severe infections in immunodeficient patients and hospitalized (Trautmann *et al.*, 2005). A group study noted that *P. aeruginosa* had the greatest burden of healthcare-acquired infections in European intensive care units (Lambert *et al.*, 2011). *P. aeruginosa* is spread in healthcare cases due it is a usual companion of patients under medical care and also it has ability existence on biotic and abiotic surfaces like medical equipment, resisting disinfection methods during transmissible from patient-to-patient (Russotto *et al.*, 2015). The isolated bacterial candidates were characterized microscopically and identified biochemically using conventional methods and were confirmed by Vitek 2 system according to previous studies (Nonhoff et al., 2005; Ligozzi et al., 2002). The utilizing traditional methods and were confirmed by Vitek 2 system according to former studies (Nonhoff *et al.*, 2005; Ligozzi *et al.*, 2002). Recently, most bacteria have the potential to develop resistance against different classes of antibiotics. Antibiotic resistance is one of the top concerns that threaten global health (CDC, 2019). Egypt is one of the countries that have less severe restrictions on antibiotic remedy (Esmael *et al.*, 2020; Esmat *et al.*, 2017).

That enhances the chance for bacteria to resist antibiotics. In the current study, antibiotic sensitivity testing of *P. aeruginosa* against a selection of fifteen antibiotics showed that the isolates resisted to most of tested antibiotics. Resistance mechanisms against antibiotics by *P. aeruginosa* were reported (Miller *et al.*, 2014). Antibiotic resistance can be developed through mutations in chromosomal genes or by mobile genetic elements (horizontally acquired resistance) (Foster, 2017). In that view, a resistance that is acquired through mutation, mechanism of horizontally acquired resistance, or overexpression of the drug efflux were discussed previously (Miller *et al.*, 2014; Jensen and Lyon, 2009). Hence, the current study used nanoparticles and bacteriophages as an alternative strategy to control the spread of these organisms. Silver compounds have been historically used to control microbial proliferation (Wadhera and Fung, 2005). The antifungal and antibacterial effect of Silver Nanoparticles AgNPs, even against antibiotic-resistant bacteria (Wright *et al.*, 1994; Wright *et al.*, 1999). Thus, nanosilver is now considered one of the most viable alternatives to antibiotics due it shows to possess high potential to solve the problem of multidrug resistance, which is often noted in several bacterial

strains (Rai et al., 2012;Salomoni et al., 2015). Chitosan has been shown to be non-toxic and tissue compatible in a range of tests. Nanoparticles, which can be produced with a wide variety of polymers and nanotechnologies, have also been recently proposed as delivery systems for peptides and proteins through the pulmonary route (Alonso, 2020).

In this respect, chitosan is avery attractive polysaccharide due to its reported low toxicity, biodegradability and mucoadhesivity (Cohen and Bernstein, 2020). Phages are small viruses which posses the capability to settle bacteria however they do not affect the cell strains from other organisms (Wittebole *et al.*, 2014). Bacteriophages are the most plentiful organisms in the biosphere (Yu *et al.*, 2017a). Phages are anywhere where their bacterial host is existent (Weinbauer, 2004). Bacteriophages play an significant role in the organization of microbial ecology, virulence and diversity (Penadés *et al.*, 2015). Bacteriophages have been sought as one of the novel therapeutic approaches to control antibiotic-resistant pathogenic bacteria (El-Dougdoug *et al.*, 2019; Shlezinger *et al.*, 2017). In the current study phage (**VB_ PseM-EB-E44)** targeted to *P. aeruginosa* -S-EB3 respectively were isolated after a screening of 100 samples of saliva in concordance with previous studies (Edlund *et al.*, 2015). Phage **VB_ PseM-EB-E44** belongs to Myoviridae. Growth kinetics of the isolated phages exhibited typical growth kinetics of most bacteriophages. Phage **VB_ PseM-EB-E44** gave burst sizes of (60) PFU/cell respectively with latent periods of (15) minutes. This value, similar to those obtained in other study with *Pseudomonas aeruginosa* phage (Kokjohn and Sayler, 1991). Where the average burst size of such phage was approximately 67 PFU/ infected cell and latent period 25 min. This phage displayed a narrow spectrum of lytic activity. This could be attributed to the ability of the tested strains to develop resistance against these phages (León and Bastías, 2015; Petty *et al.*, 2007). The host range of the isolated phage was determined against 20 bacterial isolates. this phage established

a narrow spectrum of lytic activity. Narrow host range could be overcome using a cocktail of phages (Goodridge and Bisha, 2011). In addition to that cross infectivity of phage against different species and genera was investigated in the current study, and no lytic activity was shown. The stability of phages under stressful environmental conditions promotes the application of phages as a bio-control agent in dental therapy. The **VB_ PseM-EB-E44** phage was stable at temperatures ranging from 10 to 60°C, and Ph range between H 3 and 9 for 1h.

Previous studies showed stability of phage against *P. aeruginosa* under a wide range of temperature degrees (4–60°C) (Yu, et al., 2017), and tolerance to acidic or alkaline pH (pH 3–12) (Lee et al., 2019; Rahmat Ullah et al., 2017). These findings make the isolated phage highly potent to be used in clinical settings where they can be combined with alkaline disinfectants, that are commonly used in the treatment of endodontic infections. The stability of phages under stressful environmental conditions promotes the application of phages as a bio-control agent in dental therapy.

CONCLUSION

Health concerns related to chronic wound infection have been exacerbated by antibiotic-resistant *P. aeruginosa* Hence, bacteriophage could be proposed as an alternative strategy to mitigate the causative bacterial pathogens. In this study, virulent phage was isolated for antibiotic-resistant *P. aeruginosa*, VB_PseM-EB-E44 belonged to family Myoviridae morphologically. The phage have narrow host range, low latent period, strong pH and thermal resistance. More importantly, our findings demonstrate the efficacy of phage VB_PseM-EB-E44 for the inhibition of multidrug-resistant *P. aeruginosa* growth in vitro respectively. This research forms the basis for the therapeutic application of phage to manage *P.aeruginosa* infection.

FUNDING

Funding for this paper was provided by Botany and Microbiology Department, Benha University, Egypt.

DATAA VAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

.

ETHICS STATEMENT

This article does not contain any studies with human participants or animals performed by any of the authors.

REFERENCES

Ackermann, H. W. (2012). Bacteriophage electron microscopy. *Advances in virus research*, *82*, 1-32.

Alonso, M. J. (2020). Nanoparticulate drug carrier technology. In *Microparticulate systems for the delivery of proteins and vaccines* (pp. 203-242). CRC Press.

Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., & Carmeli, Y. (2006). Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. *Antimicrobial agents and chemotherapy*, *50*(1), 43-48.

Armon, R. (2020). Bacteriophage application and biological safety (or How Should I Train My Dog Not to Bite Me). In *Biocommunication of Phages* (pp. 309-333). Springer, Cham.

Atiyeh, B. S., Costagliola, M., Hayek, S. N., & Dibo, S. A. (2007). Effect of silver on burn wound infection control and healing: review of the literature. *burns*, *33*(2), 139-148.

Ballok, A. E., & O'Toole, G. A. (2013). Pouring salt on a wound: *Pseudomonas aeruginosa* virulence factors alter Na+ and Cl− flux in the lung. *Journal of bacteriology*, *195*(18), 4013-4019.

Biemer, J. J. (1973). Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method. *Annals of Clinical & Laboratory Science*, *3*(2), 135-140.

Breidenstein, E. B., de la Fuente-Núñez, C., & Hancock, R. E. (2011). *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends in microbiology*, *19*(8), 419-426.

Burrowes, B., Harper, D. R., Anderson, J., McConville, M., & Enright, M. C. (2011). Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. *Expert review of anti-infective therapy*, *9*(9), 775-785.

Caldwell, C. C., Chen, Y., Goetzmann, H. S., Hao, Y., Borchers, M. T., Hassett, D. J., ... & Lau, G. W. (2009). *Pseudomonas aeruginosa* exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. *The American journal of pathology*, *175*(6), 2473-2488.

Chanishvili, N. (2012). Phage therapy—history from Twort and d'Herelle through Soviet experience to current approaches. *Advances in virus research*, *83*, 3-40.

Clokie, M. R., & Kropinski, A. (2009). Methods and protocols, volume 1: Isolation, characterization, and interactions. *Methods in molecular biology". Humana press*, 69-81.

Cohen, S., & Bernstein, H. (Eds.). (2020). *Microparticulate systems for the delivery of proteins and vaccines*. CRC Press.

Danis-Wlodarczyk, K., Olszak, T., Arabski, M., Wasik, S., Majkowska-Skrobek, G., Augustyniak, D., ... & Drulis-Kawa, Z. (2015). Characterization of the newly isolated lytic bacteriophages KTN6 and KT28 and their efficacy against *Pseudomonas aeruginosa* biofilm. *PloS one*, *10*(5), e0127603.

Donlan, R. M. (2001). Biofilms and device-associated infections. *Emerging infectious diseases*, *7*(2), 277.

Driscoll, J. A., Brody, S. L., & Kollef, M. H. (2007). The epidemiology, pathogenesis and treatment of *Pseudomonas aeruginosa* infections. *Drugs*, *67*(3), 351-368.

Durán, N., Marcato, P. D., De Souza, G. I., Alves, O. L., & Esposito, E. (2007). Antibacterial effect of silver nanoparticles produced by fungal process on textile fabrics and their effluent treatment. *Journal of biomedical nanotechnology*, *3*(2), 203-208.

El-Dougdoug, N. K., Cucic, S., Abdelhamid, A. G., Brovko, L., Kropinski, A. M., Griffiths, M. W., & Anany, H. (2019). Control of Salmonella Newport on cherry tomato using a cocktail of lytic bacteriophages. *International journal of food microbiology*, *293*, 60-71.

Esmael, A., Hassan, M. G., Amer, M. M., Abdelrahman, S., Hamed, A. M., Abd-Raboh, H. A., & Foda, M. F. (2020). Antimicrobial activity of certain natural-based plant oils against the antibiotic-resistant acne bacteria. *Saudi journal of biological sciences*, *27*(1), 448-455.

Esmat, M. M., Abdelhamid, A. G., Abo-ELmaaty, S. A., Nasr-Eldin, M. A., Hassan, M. G., Khattab, A. A., & Esmael, A. (2017). Antibiotics and phage sensitivity as interventions for controlling Escherichia coli isolated from clinical specimens. *Journal of Pure and Applied Microbiology*, *11*(4), 1749-1755.

Fajardo, A., & Martínez, J. L. (2008). Antibiotic resistance in *Pseudomonas*, p 177–211. *Pseudomonas* genomics and molecular biology. Caister Academic Press, Norfolk, United Kingdom.

Felix, H. (1917). Sur un microbe invisible antagoniste des bacillus dysenteriques. *Comptes rendus. Acad. Sci. Paris*, *165*, 373-375.

Foster, T. J. (2017). Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. *FEMS microbiology reviews*, *41*(3), 430-449.

George, C., Kuriakose, S., Prakashkumar, B., & Mathew, T. (2010). Synthesis, characterisation and antibacterial applications of water-soluble, silver nanoparticle-encapsulated β-cyclodextrin. *Supramolecular Chemistry*, *22*(9), 511-516.

Goodridge, L. D., & Bisha, B. (2011). Phage-based biocontrol strategies to reduce foodborne pathogens in foods. *Bacteriophage*, *1*(3), 130-137.

Gordillo Altamirano, F. L., & Barr, J. J. (2019). Phage therapy in the postantibiotic era. *Clinical microbiology reviews*, *32*(2), e00066-18.

Harper, D. R., Burrowes, B. H., & Kutter, E. M. (2014). Bacteriophage: therapeutic uses. *eLS*.

Holloway, B. W., Egan, J. B., & Monk, M. (1960). Lysogeny in *Pseudomonas aeruginosa*. *Australian Journal of Experimental Biology and Medical Science*, *38*(4), 321-330.

Huang, C., Shi, J., Ma, W., Li, Z., Wang, J., Li, J., & Wang, X. (2018). Isolation, characterization, and application of a novel specific Salmonella bacteriophage in different food matrices. *Food research international*, *111*, 631-641.

Hwang, M. G., Katayama, H., & Ohgaki, S. (2007). Inactivation of *Legionella pneumophila* and *Pseudomonas aeruginosa*: Evaluation of the bactericidal ability of silver cations. *Water Research*, *41*(18), 4097-4104.

Inglis, T. J. J. (1993). Evidence for dynamic phenomena in residual tracheal tube biofilm. *BJA: British Journal of Anaesthesia*, *70*(1), 22-24.

Kellenberger, G., & Kellenberger, E. (1957). Electron microscopical studies of phage multiplication: III. Observation of single cell bursts. *Virology*, *3*(2), 275-285.

Kerr, K. G., & Snelling, A. M. (2009). *Pseudomonas aeruginosa*: a formidable and ever-present adversary. *Journal of Hospital Infection*, *73*(4), 338-344.

Klasen, H. J. (2000). Historical review of the use of silver in the treatment of burns. I. Early uses. *Burns*, *26*(2), 117-130.

Kokjohn, T. A., & Sayler, G. S. (1991). Attachment and replication of Pseudomonas aeruginosa bacteriophages under conditions simulating aquatic environments. *Microbiology*, *137*(3), 661-666.

Kollef, M. H., Shorr, A., Tabak, Y. P., Gupta, V., Liu, L. Z., & Johannes, R. S. (2005). Epidemiology and outcomes of health-care–associated *pneumonia*: results from a large US database of culture-positive *pneumonia*. *Chest*, *128*(6), 3854-3862.

Kreuter, J. (1991). Liposomes and nanoparticles as vehicles for antibiotics. *Infection*, *19*(4), S224-S228.

Kropinski, A. M., Mazzocco, A., Waddell, T. E., Lingohr, E., & Johnson, R. P. (2009). Enumeration of bacteriophages by double agar overlay plaque assay. In *Bacteriophages* (pp. 69-76). Humana Press.

Krueger, A. P., & Scribner, E. J. (1941). The bacteriophage: its nature and its therapeutic use. *Journal of the American Medical Association*, *116*(20), 2269-2277.

Kutter, E., & Sulakvelidze, A. (Eds.). (2004). *Bacteriophages: biology and applications*. Crc press.

Lambert, M. L., Suetens, C., Savey, A., Palomar, M., Hiesmayr, M., Morales, I., ... & Wolkewitz, M. (2011). Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. *The Lancet infectious diseases*, *11*(1), 30-38.

Ligozzi, M., Bernini, C., Bonora, M. G., De Fatima, M., Zuliani, J., & Fontana, R. (2002). Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. *Journal of clinical microbiology*, *40*(5), 1681-1686.

Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009). Antibacterial-resistant *Pseudomonas aeruginosa*: *clinical* impact and complex regulation of chromosomally encoded resistance mechanisms. *Clinical microbiology reviews*, *22*(4), 582-610.

Little, J. W. (2005). Lysogeny, prophage induction, and lysogenic conversion. *Phages: their role in bacterial pathogenesis and biotechnology*, 37-54.

Maniloff, J. (2006). Virus diversity. *Biodiversity*, *7*(1), 3-8.

Meyer, J. M. (2000). Pyoverdines: pigments, siderophores and potential taxonomic markers of fluorescent *Pseudomonas* species. *Archives of microbiology*, *174*(3), 135-142.

Miller, W. R., Munita, J. M., & Arias, C. A. (2014). Mechanisms of antibiotic resistance in enterococci. *Expert review of anti-infective therapy*, *12*(10), 1221-1236.

Nonhoff, C., Rottiers, S., & Struelens, M. J. (2005). Evaluation of the Vitek 2 system for identification and antimicrobial susceptibility testing of Staphylococcus spp. *Clinical microbiology and infection*, *11*(2), 150-153.

Patey, O., McCallin, S., Mazure, H., Liddle, M., Smithyman, A., & Dublanchet, A. (2019). Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. *Viruses*, *11*(1), 18.

Penadés, J. R., Chen, J., Quiles-Puchalt, N., Carpena, N., & Novick, R. P. (2015). Bacteriophage-mediated spread of bacterial virulence genes. *Current opinion in microbiology*, *23*, 171-178.

Pereira, S. G., Rosa, A. C., Ferreira, A. S., Moreira, L. M., Proença, D. N., Morais, P. V., & Cardoso, O. (2014). Virulence factors and infection ability of *P seudomonas aeruginosa* isolates from a hydropathic facility and respiratory infections. *Journal of applied microbiology*, *116*(5), 1359-1368.

Pincus, D. H. (2006). Microbial identification using the bioMérieux Vitek® 2 system. *Encyclopedia of Rapid Microbiological Methods. Bethesda, MD: Parenteral Drug Association*, 1-32.

Reise, S. P., & Waller, N. G. (2009). Item response theory and clinical measurement. *Annual review of clinical psychology*, *5*, 27-48.

Rello, J., Ollendorf, D. A., Oster, G., Vera-Llonch, M., Bellm, L., Redman, R., & Kollef, M. H. (2002). Epidemiology and outcomes of ventilator-associated *pneumonia* in a large US database. *Chest*, *122*(6), 2115-2121.

Robertson, L. A., Cornelisse, R., De Vos, P., Hadioetomo, R., & Kuenen, J. G. (1989). Aerobic denitrification in various heterotrophic nitrifiers. *Antonie van Leeuwenhoek*, *56*(4), 289-299.

Russotto, V., Cortegiani, A., Raineri, S. M., & Giarratano, A. (2015). Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. *Journal of intensive care*, *3*(1), 1-8.

Shlezinger, M., Khalifa, L., Houri-Haddad, Y., Coppenhagen-Glazer, S., Resch, G., Que, Y. A., ... & Beyth, N. (2017). Phage therapy: a new horizon in the antibacterial treatment of oral pathogens. *Current topics in medicinal chemistry*, *17*(10), 1199-1211.

Spencer, R. C. (1999). Novel methods for the prevention of infection of intravascular devices. *Journal of Hospital Infection*, *43*, S127-S135.

Strateva, T., & Mitov, I. (2011). Contribution of an arsenal of virulence factors to pathogenesis of *Pseudomonas aeruginosa* infections. *Annals of microbiology*, *61*(4), 717-732.

Sulakvelidze, A., & Alavidze, Z. (2001). Morris JGJr. *Bacteriophage therapy. Antimicrobe Agents Chemother*, *45*, 649-59.

Szafrański, S. P., Winkel, A., & Stiesch, M. (2017). The use of bacteriophages to biocontrol oral biofilms. *Journal of biotechnology*, *250*, 29-44.

Torres-Barceló, C. (2018). The disparate effects of bacteriophages on antibiotic-resistant bacteria. *Emerging microbes & infections*, *7*(1), 1-12.

Trautmann, M., Lepper, P. M., & Haller, M. (2005). Ecology of *Pseudomonas aeruginosa* in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. *American journal of infection control*, *33*(5), S41-S49.

Twort, F. W. (1961). An investigation on the nature of ultra-microscopic viruses. *Acta Kravsi*.

Van Twest, R., & Kropinski, A. M. (2009). Bacteriophage enrichment from water and soil. In *Bacteriophages* (pp. 15-21). Humana Press.

Wadhera, A., & Fung, M. (2005). Systemic argyria associated with ingestion of colloidal silver. *Dermatology online journal*, *11*(1).

Wadhera, A., & Fung, M. (2005). Systemic argyria associated with ingestion of colloidal silver. *Dermatology online journal*, *11*(1).

Wagner, V. E., Filiatrault, M. J., Picardo, K. F., & Iglewski, B. H. (2008). *Pseudomonas aeruginosa* virulence and pathogenesis issues. *Pseudomonas genomics and molecular biology*, 129-158.

Wang, I. N., Smith, D. L., & Young, R. (2000). Holins: the protein clocks of bacteriophage infections. *Annual Reviews in Microbiology*, *54*(1), 799-825.

Wayne, P. A. (2010). Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: 20th informational supplement. *CLSI document M100-S20*.

Weinbauer, M. G., & Rassoulzadegan, F. (2004). Are viruses driving microbial diversification and diversity?. *Environmental microbiology*, *6*(1), 1-11.

Wittebole, X., De Roock, S., & Opal, S. M. (2014). A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence*, *5*(1), 226-235.

Wright, J. B., Lam, K., & Burrell, R. E. (1998). Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. *American journal of infection control*, *26*(6), 572-577.

Wright, J. B., Lam, K., Hansen, D., & Burrell, R. E. (1999). Efficacy of topical silver against fungal burn wound pathogens. *American journal of infection control*, *27*(4), 344-350.

Yang, L., Jelsbak, L., Marvig, R. L., Damkiær, S., Workman, C. T., Rau, M. H., ... & Molin, S. (2011). Evolutionary dynamics of bacteria in a human host environment. *Proceedings of the National Academy of Sciences*, *108*(18), 7481-7486.

Young, G. (1947). Pigment production and antibiotic activity in cultures of *Pseudomonas aeruginosa*. *Journal of bacteriology*, *54*(2), 109-117.

Supplementary data

Table S1. Biochemical characterization of *Pseudomonas aeruginosa* clinically isolated from patients with Chronic wound

Morphological characteristics and Biochemical tests	***P. aeruginosa***
M0tility	+
Gram reaction	(-ve)
Shape	rods
Citrate utilization	+
Indole	-
Methiyl reduction	-
Oxidase	+
Catlase	+
Urease	-
Voges proskaur	-
Glucose	+
Mannitol	-
Sucrose	+
Lactose	-
Starch	+
Hemolysis (Beta-hemolysis)	+

Figure S1. Antibiotic susceptibility test showing zones of clearance surrounding Antibiotic Discs: Multidrug resistance *P. aeruginosa-S-EB3* (A-D), against a selection of 15 antibiotics.



View publication stats